Article
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
Antiviral therapy - 1 Jan 2015
Eron Joseph J, Cooper David A, Steigbigel Roy T, Clotet Bonaventura, Yeni Patrick, Strohmaier Kim M, Rodgers Anthony J, Barnard Richard J, Nguyen Bach-Yen T, Teppler Hedy
Abstract excerpt
BACKGROUND: We explored the relationship between virological response in the first year of treatment and long-term outcomes in the BENCHMRK studies. METHODS: Patients failing antiretroviral treatment with 3-class resistant HIV-1 received double-blinded raltegravir (or placebo) with optimized background therapy (OBT) until week 156, followed by open-label raltegravir with OBT up to week 240. In this exploratory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.